

## Purified anti-mouse Ki-67 Antibody

<b>Catalog# / Size</b>	652401 / 25 µg 652402 / 100 µg
<b>Clone</b>	16A8
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	KiA, proliferation-related Ki-67 antigen
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	The nuclear protein Ki-67 was first identified by the monoclonal antibody Ki-67, which was generated by immunizing mice with nuclei of the L428 Hodgkin lymphoma cell line. Ki-67 protein plays an essential role in ribosomal RNA transcription and cell proliferation. Expression of Ki-67 occurs during G1, S, G2, and M phase, while in G0 phase the Ki-67 protein is not detectable. Ki-67 is strongly expressed in proliferating cells and has been reported as a prognostic marker in various tumors.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	<i>E. coli</i> expressed partial mouse Ki-67 recombinant protein, 1816-2163 aa.
<b>Formulation</b>	This antibody is provided in phosphate-buffered solution, pH 7.2, containing 0.05% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	Upon receipt, store undiluted between 2°C and 8°C.
<b>Application</b>	<a href="#">FC - Quality tested</a> <a href="#">WB, ICC, IHC-F - Verified</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µl volume. For western blotting, suggested working dilution(s): Use 5 µl per 5 ml antibody dilution buffer for each mini-gel (0.5 µg/ml). For immunocytochemistry, a concentration range of 1.25 - 5.0 µg/mL is recommended. For immunohistochemistry on frozen tissue sections, a concentration range of 2.5 - 10.0 µg/mL is suggested. Additionally, each lot of this antibody is quality control tested by our Ki-67 staining protocol below. It is recommended that the reagent be titrated for optimal performance for each application.

### Application References

(PubMed link indicates BioLegend citation)

1. Medina-Reyes EI, *et al.* 2015. *Environ Res.* 136:424. [PubMed](#)
2. Guillaumond F, *et al.* 2015. *PNAS.* 112:2473. [PubMed](#)
3. Sharma SK, *et al.* 2015. *J Immunol.* 194:5529. [PubMed](#)
4. Rodero MP, *et al.* 2014. *J. Invest. Dermatol.* 7:1991-7. [PubMed](#)

### Product Citations

1. Arnold IC, *et al.* 2019. *PLoS Pathog.* 15:e1007866. [PubMed](#)
2. Minamide K, *et al.* 2020. *Sci Rep.* 10:14639. [PubMed](#)
3. Herring CA *et al.* 2017. *Cell systems.* 6(1):37-51. [PubMed](#)
4. Xu L, *et al.* 2017. *Int J Biol Macromol.* . 10.1016/j.ijbiomac.2017.07.090. [PubMed](#)
5. von Klitzing E, *et al.* 2018. *Sci Rep.* 20:594. [PubMed](#)
6. Yuan CL, *et al.* 2018. *Exp Ther Med.* 9:1420. [PubMed](#)
7. Medina-Reyes E, *et al.* 2015. *Environ Res.* 136:424. [PubMed](#)
8. Heimesaat MM, *et al.* 2018. *Eur J Microbiol Immunol (Bp).* 1864:1609. [PubMed](#)
9. Zingg D *et al.* 2018. *Cancer cell.* 34(1):69-84. [PubMed](#)
10. Mayer KA, *et al.* 2021. *FASEB J.* 35:e21217. [PubMed](#)
11. Zappasodi R, *et al.* 2021. *Nature.* 591:652. [PubMed](#)

12. Marable SS, *et al.* 2020. *J Am Soc Nephrol.* 2543:31. [PubMed](#)
13. Javary J, *et al.* 2021. *Liver Int.* 41:1423. [PubMed](#)
14. Brown EM, *et al.* 2019. *Cell Host Microbe.* 25:668. [PubMed](#)
15. Yang SH, *et al.* 2017. *Front Immunol.* 8:1192. [PubMed](#)
16. Matsumoto Y, *et al.* 2019. *Sci Rep.* 9:15244. [PubMed](#)
17. Zhao L, *et al.* 2018. *Nat Med.* 24:1536. [PubMed](#)
18. Hallam D, *et al.* 2015. *Exp Gerontol.* 67: 72-79. [PubMed](#)
19. Hsiao CC, *et al.* 2021. *Cells.* 10:. [PubMed](#)
20. Horiuchi S, *et al.* 2021. *Sci Immunol.* :eabm3131. [PubMed](#)
21. Rore H, *et al.* 2021. *Commun Biol.* 4:802. [PubMed](#)
22. Johnson SA, *et al.* 2021. *Eur J Immunol.* 51:3228. [PubMed](#)
23. Guillaumond F, *et al.* 2015. *Proc Natl Acad Sci U S A.* 112:2473. [PubMed](#)
24. Wang C, *et al.* 2016. *J Cell Biol.* 212: 545-60. [PubMed](#)
25. Hollinshead KER, *et al.* 2020. *Cell Rep.* 33:108231. [PubMed](#)
26. Clark K, *et al.* 2019. *Front Immunol.* 10:2355. [PubMed](#)
27. Men L, *et al.* 2018. *Cell Physiol Biochem.* 51:2185. [PubMed](#)
28. Villarreal-Ponce A, *et al.* 2020. *Cell Rep.* 33:108417. [PubMed](#)
29. Lkhagvadorj K, *et al.* 2020. *Am J Physiol Lung Cell Mol Physiol.* 319:L742. [PubMed](#)
30. Heimesaat MM, *et al.* 2019. *Front Immunol.* 10:49. [PubMed](#)
31. Miller AJ, *et al.* 2020. *Dev Cell.* 117:53. [PubMed](#)
32. Scortegagna M, *et al.* 2020. *Nat Commun.* 11:99. [PubMed](#)
33. Klose A, *et al.* 2018. *JCSM Rapid Commun.* 9:20222. [PubMed](#)
34. Matsumori T, *et al.* 2020. *Cancer Res.* 80:5305. [PubMed](#)
35. Wang G, *et al.* 2019. *Front Immunol.* 1.380555556. [PubMed](#)
36. Stelekati E, *et al.* 2018. *Cell Rep.* 2.445833333. [PubMed](#)
37. Madouri F, *et al.* 2017. *J Allergy Clin Immunol.* 139:1650. [PubMed](#)
38. Maier B, *et al.* 2020. *Nature.* 580:257. [PubMed](#)
39. Lee J, *et al.* 2019. *Yonsei Med J.* 60:667. [PubMed](#)
40. Hennchen M, *et al.* 2015. *J Neurosci.* 35: 16531 - 16544. [PubMed](#)
41. Chen M, *et al.* 2018. *Am J Physiol Endocrinol Metab.* 315:E72. [PubMed](#)

**RRID** AB\_11203533 (BioLegend Cat. No. 652401)  
 AB\_11204254 (BioLegend Cat. No. 652402)

## Antigen Details

---

<b>Structure</b>	325 kD protein containing a forkhead-associated domain (FHA) and 13 tandem repeats
<b>Distribution</b>	Nucleus and chromosome
<b>Function</b>	Required for cell cycle progression and proliferation
<b>Interaction</b>	Interacts with KIF15; binds to MKI67IP through FHA domain
<b>Biology Area</b>	Cell Biology, Cell Cycle/DNA Replication, Transcription Factors
<b>Molecular Family</b>	Nuclear Markers
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Starborg M, <i>et al.</i> 1996. <i>J. Cell. Sci.</i> 109:143.</li> <li>2. Byeon IJ, <i>et al.</i> 2005. <i>Nat. Struct. Mol. Biol.</i> 12:987.</li> <li>3. Yerushalmi R, <i>et al.</i> 2010. <i>Lancet. Oncol.</i> 11:174.</li> <li>4. Beltrami AP, <i>et al.</i> 2001. <i>N. Engl. J. Med.</i> 344:1750.</li> <li>5. Sachsenberg N, <i>et al.</i> 1998. <i>J. Exp. Med.</i> 187:1295.</li> <li>6. Nagy Z, <i>et al.</i> 1997. <i>Acta. Neuropathol.</i> 93:294.</li> </ol>
<b>Gene ID</b>	<a href="#">17345</a>

## Related Protocols

---

[Immunohistochemistry Protocol for Frozen Sections](#)

[Cell Surface Flow Cytometry Staining Protocol](#)

[Immunocytochemistry Staining Protocol](#)


[Western Blotting Protocol](#)

[Ki-67 Flow Cytometry Staining Protocol](#)


## Other Formats

Purified anti-mouse Ki-67, PE anti-mouse Ki-67, APC anti-mouse Ki-67, Alexa Fluor® 647 anti-mouse Ki-67, FITC anti-mouse Ki-67, Brilliant Violet 421™ anti-mouse Ki-67, Brilliant Violet 605™ anti-mouse Ki-67, Alexa Fluor® 488 anti-mouse Ki-67, Alexa Fluor® 700 anti-mouse Ki-67, Pacific Blue™ anti-mouse Ki-67, PerCP/Cyanine5.5 anti-mouse Ki-67, PE/Cyanine7 anti-mouse Ki-67, PE/Dazzle™ 594 anti-mouse Ki-67


## Product Data




Con A-stimulated (3 days) C57BL/6 mouse splenocytes were fixed and permeabilized with 70% ethanol, then stained with Ki-67 (clone 16A8) purified antibody (filled histogram) or rat IgG2a, κ isotype control (open histogram) followed by anti-rat IgG PE.



Total cell lysates (15 μg protein) from Raw264.7 and NIH3T3 were resolved by 3-8% Tris-Acetate gel electrophoresis, transferred to nitrocellulose, and probed with mouse Ki-67 antibody (clone 16A8). Proteins were visualized using a goat anti-rat IgG secondary antibody conjugated to HRP and chemiluminescence detection. Direct-Blot™ HRP anti-β-actin was used as a loading control.



TE-71 cells were fixed with 1% paraformaldehyde (PFA) for ten minutes, permeabilized with 0.5% Triton X-100 for ten minutes, and blocked with 5% FBS for 30 minutes. Then the cells were intracellularly stained with 2.5 μg/mL of purified Ki-67 (clone 16A8) in 5% FBS overnight at 4°C, followed by Alexa Fluor® 647 goat anti-rat IgG (clone Poly4054, red) for two hours. Nuclei were counterstained with DAPI (blue). The image was captured with a 40X objective.



C57BL/6 mouse frozen intestine section was fixed with 4% paraformaldehyde (PFA) for ten minutes, permeabilized with 0.5% Triton X-100 for ten minutes, and blocked with 5% FBS plus 5% goat serum for 30 minutes at room temperature. Then the section was stained with 5 µg/mL purified Ki-67 (clone 16A8) in 5% FBS overnight at 4°C, followed by Alexa Fluor® 647 goat anti-rat IgG (clone Poly4054, red). Nuclei were counterstained with DAPI (blue). The image was captured with a 10X objective.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587